Phase II Study of Pemetrexed in Patients Pretreated with an Anthracycline, a Taxane, and Capecitabine for Advanced Breast Cancer
- 1 June 2005
- journal article
- clinical trial
- Published by Elsevier in Clinical Breast Cancer
- Vol. 6 (2) , 143-149
- https://doi.org/10.3816/cbc.2005.n.016
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclinesAnnals of Oncology, 2003
- Pemetrexed (Alimta®): a novel multitargeted antifolate agentExpert Review of Anticancer Therapy, 2003
- Treatment for Anthracycline-Pretreated Metastatic Breast CancerThe Oncologist, 2002
- Single‐Agent Capecitabine: A Reference Treatment for Taxane‐Pretreated Metastatic Breast Cancer?The Oncologist, 2002
- A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancerEuropean Journal Of Cancer, 2001
- Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)Advances in Enzyme Regulation, 1998
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissuePublished by Elsevier ,1998
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom ChecklistBritish Journal of Cancer, 1990